Grant of awards under Long Term Incentive Plan

hVIVO PLC

29 May 2026

 

hVIVO plc

("hVIVO, the "Company" or the "Group")

Grant of awards under Long Term Incentive Plan

London, UK - 29 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that on 28 May 2026, the Company awarded 10,159,068 options under the hVIVO Long Term Incentive Plan 2024 to certain senior management, including its Chief Executive Officer and Chief Financial Officer as set out in the table below. The award is over ordinary shares of £0.001 ("Ordinary Shares") in the form of options to acquire Ordinary Shares at nominal value ("LTIP Awards").

Executive	Role	Number of LTIP Awards
Yamin 'Mo' Khan	Chief Executive Officer	6,126,238
Stephen Pinkerton	Chief Financial Officer	2,289,604

The LTIP Awards will vest on the third anniversary of grant subject to meeting a minimum absolute total shareholder return (TSR) of 10% CAGR and mid-single digit £ million adjusted EBITDA,  weighted equally, over the three-year period ending 31 December 2028.

25% of the LTIP Awards will vest on meeting the minimum threshold performance criteria outlined above, with vesting thereafter on a straight-line basis up to meeting a maximum performance target which would be achieved in the event of a 20% absolute TSR being met and a significant increase in adjusted EBITDA from the minimum threshold number.

The awards are subject to malus and clawback provisions. In making its determination in relation to the achievement of any performance target or condition under these Rules, the Remuneration Committee may, in line with the UK Corporate Governance Code, exercise its discretion to override formulaic outcomes. This includes, without limitation, to reflect overall corporate performance, the value created for shareholders, or where the business has suffered an exceptional negative event.

For further information please contact:

hVIVO plc		[phone]
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				[phone]
Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)			[phone]
James Steel, Dr Christopher Golden
Davy (Euronext Growth Adviser and Joint Broker)			[phone]
Anthony Farrell, Niall Gilchrist
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson		[e-mail]

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

Notes to Editors

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

·    Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.

·    Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.

·    Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014: 

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name	Yamin 'Mo' Khan
2	Reason for the notification
(a)	Position/status	Chief Executive Officer
(b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
(a)	Name	hVIVO plc
(b)	LEI	213800VT5KBM7JLIV118
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary shares of £0.001 pence each ISIN GB00B9275X97
(b)	Nature of the transaction	Award of options pursuant to hVivo plc 2024 Long Term Incentive Plan
(c)	Price(s) and volume(s)	Price(s) Volume(s) £0.001 6,126,238
(d)	Aggregated information -         Aggregated volume -         Price	N/A
(e)	Date of the transaction	28 May 2026
(f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name	Stephen Pinkerton
2	Reason for the notification
(a)	Position/status	Chief Financial Officer
(b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
(a)	Name	hVIVO plc
(b)	LEI	213800VT5KBM7JLIV118
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary shares of £0.001 pence each ISIN GB00B9275X97
(b)	Nature of the transaction	Award of options pursuant to hVIVO plc 2024 Long Term Incentive Plan
(c)	Price(s) and volume(s)	Price(s) Volume(s) £0.001 2,289,604
(d)	Aggregated information -         Aggregated volume -         Price	N/A
(e)	Date of the transaction	28 May 2026
(f)	Place of the transaction	Outside a trading venue

 

END